Medicamen Organ.

Which are the latest news on Medicamen Organ.?

Why is Medicamen Organics Ltd falling/rising?

As of 05-Sep, Medicamen Organics Ltd's stock price is rising to 26.50, up 3.31%, driven by strong relative performance and trading above key moving averages. Increased investor participation, evidenced by a significant rise in delivery volume, indicates growing confidence in the stock.

As of 05-Sep, Medicamen Organics Ltd's stock price is rising, currently at 26.50, reflecting an increase of 0.85 or 3.31%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 3.76% today, indicating strong relative performance. Additionally, it is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which suggests a positive trend in its price movement.<BR><BR>Moreover, there has been a notable increase in investor participation, with delivery volume on September 2 rising by 118.75% compared to the 5-day average. This surge in trading activity often signals increased investor interest and confidence in the stock. Overall, these factors contribute to the stock's rising price, despite a mixed performance over longer periods, such as a decline of 11.22% over the past month.

What does Medicamen Organ. do?

Medicamen Organics Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 1995. It currently has a market cap of INR 36 Cr, with no available data on net sales or profit.

Overview:<BR>Medicamen Organics Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Medicamen Organics Ltd was incorporated on March 15, 1995, originally as Panchdeep Pharmaceuticals Limited. The company changed its name to Medicamen Organics Limited and received a fresh Certificate of Incorporation on November 14, 1995. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 36 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A<BR>Industry P/E: 37<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.40<BR>Return on Equity: -9.87%<BR>Price-to-Book: 1.18<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the peers of the Medicamen Organ.?

Peers of Medicamen Organ. include JFL Life, Lasa Supergeneri, Medi Caps, Guj. Terce Labs., Sandu Pharma., Cian Healthcare, Vista Pharma., Welcure Drugs, Chandra Bhagat, and Venmax Drugs. JFL Life shows excellent management risk and growth, while Medicamen Organ. has below average management risk and growth, with a 1-year return of -29.63%.

Peers: The peers of Medicamen Organ. are JFL Life, Lasa Supergeneri, Medi Caps, Guj. Terce Labs., Sandu Pharma., Cian Healthcare, Vista Pharma., Welcure Drugs, Chandra Bhagat, and Venmax Drugs.<BR><BR>Quality Snapshot: Excellent management risk is observed at JFL Life, while Average management risk is found at Sandu Pharma. and Welcure Drugs. Below Average management risk is noted for Medicamen Organ., Lasa Supergeneri, Medi Caps, Guj. Terce Labs., Cian Healthcare, Vista Pharma., Chandra Bhagat, and Venmax Drugs. Growth is Excellent at JFL Life, Average at Guj. Terce Labs., and Below Average at Medicamen Organ., Lasa Supergeneri, Medi Caps, Sandu Pharma., Cian Healthcare, Vista Pharma., Welcure Drugs, Chandra Bhagat, and Venmax Drugs. Capital Structure is Good at JFL Life, Medi Caps, Sandu Pharma., and Welcure Drugs, while Average is seen at Lasa Supergeneri, and Below Average at Medicamen Organ., Guj. Terce Labs., Cian Healthcare, Vista Pharma., Chandra Bhagat, and Venmax Drugs.<BR><BR>Return Snapshot: JFL Life has the highest 1-year return at -29.00%, while Medicamen Organ. has the lowest at -29.63%. Medicamen Organ.'s 1-year return is slightly worse than JFL Life's. Additionally, Lasa Supergeneri, Medi Caps, Guj. Terce Labs., Cian Healthcare, Vista Pharma., Welcure Drugs, Chandra Bhagat, and Venmax Drugs all have a six-month return of 0.00%.

How big is Medicamen Organ.?

As of 14th August, Medicamen Organics Ltd has a market capitalization of 30.00 Cr, classified as a Micro Cap, with no valid financial data available for Net Sales and Net Profit for the latest four quarters. The latest annual reporting period shows Shareholder's Funds at 30.13 Cr and Total Assets at 59.21 Cr.

As of 14th August, <BR><BR>Market Cap: Medicamen Organics Ltd has a market capitalization of 30.00 Cr, categorized as a Micro Cap.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The latest annual reporting period is March 2025, with Shareholder's Funds reported at 30.13 Cr and Total Assets at 59.21 Cr.

Is Medicamen Organ. overvalued or undervalued?

As of December 3, 2025, Medicamen Organ. is considered undervalued with a PE ratio of 9.64 and attractive valuation metrics compared to peers like Sun Pharma and Divi's Lab, making it a compelling investment opportunity despite a challenging year.

As of 3 December 2025, Medicamen Organ. has moved from a fair to an attractive valuation grade, indicating a shift in its market perception. The company is currently considered undervalued, with a PE ratio of 9.64, an EV to EBIT of 9.14, and an EV to EBITDA of 7.92, which are significantly lower than its peers. For instance, Sun Pharma. has a PE ratio of 37.51 and an EV to EBITDA of 24.8, while Divi's Lab. shows a PE of 68.92 and an EV to EBITDA of 51.79, highlighting the relative attractiveness of Medicamen's valuation.<BR><BR>In comparison to its peers, Medicamen Organ. stands out with a PEG ratio of 0.00, suggesting that it is priced favorably relative to its growth prospects. Other attractive peers include Cipla and Dr. Reddy's Labs, with PE ratios of 22.39 and 18.52, respectively. Despite a challenging year with a YTD return of -50%, the valuation metrics suggest that Medicamen Organ. presents a compelling investment opportunity in the pharmaceuticals and biotechnology sector.

How has been the historical performance of Medicamen Organ.?

Medicamen Organ experienced significant financial growth from March 2024 to March 2025, with net sales rising to 38.19 Cr and profit after tax increasing to 4.05 Cr. Key metrics such as operating profit and earnings per share also improved, indicating strong overall performance.

Answer:<BR>The historical performance of Medicamen Organ shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Medicamen Organ's net sales increased from 25.27 Cr in March 2024 to 38.19 Cr in March 2025, contributing to a total operating income rise to 38.19 Cr from 25.27 Cr. The company's total expenditure also grew, reaching 31.60 Cr from 20.53 Cr, primarily driven by higher raw material costs, which rose to 22.25 Cr from 14.40 Cr. Operating profit (PBDIT) improved to 6.69 Cr from 5.81 Cr, although the operating profit margin decreased slightly to 17.26% from 18.76%. Profit before tax increased to 5.43 Cr from 4.44 Cr, leading to a profit after tax of 4.05 Cr, up from 2.62 Cr. The company's earnings per share rose to 3.46 from 3.05, while the book value per share increased to 25.11 from 17.74. On the balance sheet, total assets grew to 59.21 Cr from 38.44 Cr, with total liabilities also increasing to 59.21 Cr from 38.44 Cr. Cash flow from financing activities saw a notable increase to 10.00 Cr from 4.00 Cr, resulting in a net cash inflow of 3.00 Cr compared to no inflow in the previous year. Overall, Medicamen Organ demonstrated a strong financial performance with growth across key metrics.

What is the technical trend for Medicamen?

As of June 3, 2025, Medicamen's technical trend is mildly bullish, supported by the weekly MACD, Bollinger Bands, and Dow Theory, despite some caution from daily moving averages and a bearish weekly KST.

As of 3 June 2025, the technical trend for Medicamen has changed from sideways to mildly bullish. The weekly MACD indicates a mildly bullish stance, while the Bollinger Bands also reflect a bullish condition. The Dow Theory supports this with a mildly bullish signal on both weekly and monthly time frames. However, the daily moving averages are mildly bearish, which introduces some caution. The weekly KST is bearish, but the OBV shows a mildly bullish trend. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD, Bollinger Bands, and Dow Theory indicators.

Who are the top shareholders of the Medicamen?

The top shareholders of Medicamen include Bal Kishan Gupta with 52.16%, followed by public shareholder Shivani Chopra at 5.13%. Individual investors collectively hold 28.79%, and there is one Foreign Institutional Investor with a 0.07% stake.

The top shareholders of Medicamen include the promoters, with Bal Kishan Gupta holding the highest share at 52.16%. There are no pledged promoter holdings, and the company has one Foreign Institutional Investor (FII) holding 0.07%. The highest public shareholder is Shivani Chopra, who owns 5.13%. Additionally, individual investors collectively hold 28.79% of the shares.

When is the next results date for Medicamen?

No Upcoming Board Meetings

Has Medicamen declared dividend?

No Dividend History Available